Static Chart FUSN PHAR

Equities

Market Closed - Nasdaq Other stock markets 21:00:00 17/05/2024 BST			5-day change	1st Jan Change
21.51 ^USD	+0.23%		+0.61%	+123.83%

05-09	Fusion Pharmaceuticals Inc. Announces First Patient Dosed in the Phase 2 Portion of the AlphaBreak Trial Evaluating FPI-2265 in Metastatic Castration-Resistant Prostate Cancer	CI
05-07	Fusion Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Duration

Period